B2M and lymphoma: Another way to test the predictive value of cystatin C in disease monitoring was to compare its level with established biochemical (CRP, β2M, and LDH levels), clinical parameters of disease progression (the presence of B symptoms, clinical stage, age, and IPI) and with the levels of IL-6, as prognostic factor in patients with lymphoma [9].